PODD Quote, Financials, Valuation and Earnings

Boston Scientific has a net margin of 16.85% compared to Insulet's net margin of 12.41%. Insulet's return on equity of 43.11% beat Boston Scientific's return on equity of 8.96%.

Insulet has a consensus price target of $312.92, signalling upside risk potential of 18.21%. On the other hand Boston Scientific has an analysts' consensus of $115.37 which suggests that it could grow by 19.22%. Given that Boston Scientific has higher upside potential than Insulet, analysts believe Boston Scientific is more attractive than Insulet.

Insulet has a beta of 1.300, which suggesting that the stock is 30.008% more volatile than S&P 500. In comparison Boston Scientific has a beta of 0.728, suggesting its less volatile than the S&P 500 by 27.188%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Boston Scientific offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Boston Scientific pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $597.5M, which are smaller than Boston Scientific quarterly revenues of $4.6B. Insulet's net income of $100.7M is lower than Boston Scientific's net income of $566M. Notably, Insulet's price-to-earnings ratio is 45.72x while Boston Scientific's PE ratio is 77.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 9.44x versus 8.59x for Boston Scientific. Usually stocks with elevated PS ratios are considered overvalued.

Masimo has a net margin of 16.85% compared to Insulet's net margin of -58.2%. Insulet's return on equity of 43.11% beat Masimo's return on equity of -23.05%.

Insulet has a consensus price target of $312.92, signalling upside risk potential of 18.21%. On the other hand Masimo has an analysts' consensus of $195.70 which suggests that it could grow by 18.91%. Given that Masimo has higher upside potential than Insulet, analysts believe Masimo is more attractive than Insulet.

Insulet has a beta of 1.300, which suggesting that the stock is 30.008% more volatile than S&P 500. In comparison Masimo has a beta of 1.278, suggesting its more volatile than the S&P 500 by 27.807%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Masimo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Masimo pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $597.5M, which are smaller than Masimo quarterly revenues of $600.7M. Insulet's net income of $100.7M is higher than Masimo's net income of -$349.6M. Notably, Insulet's price-to-earnings ratio is 45.72x while Masimo's PE ratio is 116.80x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 9.44x versus 4.25x for Masimo. Usually stocks with elevated PS ratios are considered overvalued.

Stryker has a net margin of 16.85% compared to Insulet's net margin of 8.48%. Insulet's return on equity of 43.11% beat Stryker's return on equity of 15.22%.

Insulet has a consensus price target of $312.92, signalling upside risk potential of 18.21%. On the other hand Stryker has an analysts' consensus of $423.15 which suggests that it could grow by 16.58%. Given that Insulet has higher upside potential than Stryker, analysts believe Insulet is more attractive than Stryker.

Insulet has a beta of 1.300, which suggesting that the stock is 30.008% more volatile than S&P 500. In comparison Stryker has a beta of 0.929, suggesting its less volatile than the S&P 500 by 7.107%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Stryker offers a yield of 0.9% to investors and pays a quarterly dividend of $0.84 per share. Insulet pays -- of its earnings as a dividend. Stryker pays out 40.73% of its earnings as a dividend. Stryker's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Insulet quarterly revenues are $597.5M, which are smaller than Stryker quarterly revenues of $6.4B. Insulet's net income of $100.7M is lower than Stryker's net income of $546M. Notably, Insulet's price-to-earnings ratio is 45.72x while Stryker's PE ratio is 46.77x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 9.44x versus 6.19x for Stryker. Usually stocks with elevated PS ratios are considered overvalued.

Tandem Diabetes Care has a net margin of 16.85% compared to Insulet's net margin of 0.27%. Insulet's return on equity of 43.11% beat Tandem Diabetes Care's return on equity of -37.18%.

Insulet has a consensus price target of $312.92, signalling upside risk potential of 18.21%. On the other hand Tandem Diabetes Care has an analysts' consensus of $39.81 which suggests that it could grow by 126.06%. Given that Tandem Diabetes Care has higher upside potential than Insulet, analysts believe Tandem Diabetes Care is more attractive than Insulet.

Insulet has a beta of 1.300, which suggesting that the stock is 30.008% more volatile than S&P 500. In comparison Tandem Diabetes Care has a beta of 1.525, suggesting its more volatile than the S&P 500 by 52.461%.

Insulet has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tandem Diabetes Care offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Insulet pays -- of its earnings as a dividend. Tandem Diabetes Care pays out -- of its earnings as a dividend.

Insulet quarterly revenues are $597.5M, which are larger than Tandem Diabetes Care quarterly revenues of $282.6M. Insulet's net income of $100.7M is higher than Tandem Diabetes Care's net income of $755K. Notably, Insulet's price-to-earnings ratio is 45.72x while Tandem Diabetes Care's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Insulet is 9.44x versus 1.23x for Tandem Diabetes Care. Usually stocks with elevated PS ratios are considered overvalued.